Pathogen reduction technologies: What are the concerns?

Vox Sanguinis, Supplement

Volumn 87, Issue 2, 2004, Pages

  AuBuchon, James P ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD STORAGE; BLOODBORNE VIRUS; CONFERENCE PAPER; ENVELOPED VIRUS; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE MEMBRANE; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL CIRCULATION; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; ISOTOPE LABELING; LEUKOCYTE; MEDICAL DOCUMENTATION; MEDICAL TECHNOLOGY; MEMBRANE ELASTICITY; NONENVELOPED VIRUS; OUTCOMES RESEARCH; PATHOGEN REDUCTION TECHNOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SAFETY; STORAGE TIME; THROMBOCYTE LIFESPAN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSION; VIRAL CONTAMINATION; VIRION; VIRUS; VIRUS GENOME; VIRUS INACTIVATION; VIRUS LOAD; VIRUS TITRATION; WEST NILE FLAVIVIRUS;

BACTERIAL INFECTIONS; BLOOD; BLOOD BANKS; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD TRANSFUSION; ERYTHROCYTES; HUMANS; PLASMA; QUALITY ASSURANCE, HEALTH CARE; RISK; SAFETY; VIRUS DISEASES;

EID: 4444347754     PISSN: 17416892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Berwick DM: Disseminating innovations in health care. JAMA 2003; 289:1969-75
2. Goldfinger D, Klapper E, Pepkowitz S, Millar SI, Heal JM, Blumberg N, Wuest D, Reich C, Mayer K: Universal WBC reduction and patient advocacy. Transfusion 2000; 40:1545-6
3. Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959-62
4. Busch M, Giachetti C, Conrad A, Gallarda A, Mimms LT, Peddada L, Charles H, Raia S, Fiebig EW, Wright D: Dynamics of HCV viremia during early HCV infection: Implications for minipool (MP) vs individual donation (ID) nucleic acid amplification testing (NAT). (Abstract) Transfusion 2000; 40:25S-6S
5. Peddada L, Heldebrant C, Smith R, Conrad A, Raia S, Wright D, Fiebig EW, Busch MP: HBV viremia preceding HBsAg positivity: Implications for minipool (MP) and individual donation (ID) HBV nucleic acid testing (NAT). (Abstract) Transfusion 2000; 40:14S-5S
6. Epstein JS, Vostal JG: FDA approach to evaluation of pathogen reduction technology. Transfusion 2003; 43:1347-50
7. Hollinger FB, Kleinman S: Transfusion transmission of west nile virus: A merging of historical and contemporal perspectives. Transfusion 2003; 43:992-7
8. Murphy S, Rebulla P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg RR for the BEST (Biomedical Excellence for Safer Transfusion) Task Force of the ISBT: In vitro assessment of the quality of stored platelet concentrates. Transfus Med Rev 1994; 8:29-36
9. Holme S: Storage and quality assessment of platelets. Vox Sang 1998; 74:207-16
10. Verhoeven AJ, Hilarius PM, Ebbing IG, Dekkers DW, Lagerberg JW, De Korte D: Activation of scramblase as a result of photodynamic treatment of red blood cells. Transfusion 2003; 43:88a
11. Snyder E, Mintz P, Burks S, Haverstick D, Baril L, Dzik W, Purmal A, Beach K: Pathogen inactivated red blood cells using INACTINE technology demonstrate 24 hour post transfusion recovery equal to untreated red cells after 42 days of storage. Blood 2001; 98:709-10a
12. Murphy S: Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004; 44:131-3
13. AuBuchon JP, Herschel L, Roger J, Murphy S: Preliminary validation of a new standard of efficacy for stored platelets. Transfusion 2003; 43:29a
14. AuBuchon JP, Herschel L, Roger J, Murphy S: Preliminary validation of a new standard of efficacy for stored platelets. Transfusion 2004; 44:36-41
15. Hanson SR, Slichter SJ: Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 1985; 66:1105-9
16. Kruskall MS, AuBuchon JP, Anthony KY, Herschel L, Pickard C, Biehl R, Horowitz M, Brambilla DJ, Popovsky MA: Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O. Transfusion 2000; 40:1290-8
17. Davis KB, Slichter SJ, Corash L: Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: Problems and a solution. Transfusion 1999; 39:586-92
18. McCullough J, Vesole D, Benjamin RJ, Slichter S, Pineda A, Snyder E, Stadtmauer E, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey J, Raife T, Cable R, Murphy S, Howard F, Davis K, Koutsoukas A, Lin L, Metzel P, Buchholz DH, Corash L, Conlan MG: Pathogen inactivated platelets (plt) using Helinx technology (Intercept plt) are hemostatically effective thrombocytopenic patients (Tcp Pts) Blood 2001; 98:450a
19. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P, BEST Working Party: Methodological issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43:742-52
20. International Committee for Harmonization. ICH Topic E9: Statistical principles for clinical trials. Federal Register 1998; 63:no.179
21. AuBuchon JP, Cooper LK, Leach MF, Zuaro DE, Schwartzman JD: Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service. Transfusion 2002; 42:855-61
22. Dodd RY: Bacterial contamination and transfusion safety: Experience in the United States. Transfus Clin Biol 2003; 10:6-9
23. Ness P, Braine H, King K, Barrasso C, Kickler T, Fuller A, Blades N: Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41:857-61
24. Weekly Report: Baxter and Cerus halt late-stage RBC pathogen inactivation trials. Bethesda, MD, USA AABB, 2003; 9,no.31:5
25. VI Technologies: Vitex halts enrollment in phase III chronic trial of the Inactine™ pathogen reduction system for red blood cells. 17 November 2003 Press release, http://www.vitechnologies.com/press_releases/archives/11-17-03a. htm
26. Brecher ME, Hay SN: The role of bacterial testing of cellular blood products in light of new pathogen inactivation technologies. Blood Therapies Med 2003; 3:49-55
27. Council of Europe: Recommendation Rec (2003) 11 of the Committee of Ministers to member states on the introduction of pathogen inactivation procedures for blood components. http://www.coe.International/T/E/ Social_Cohesion/Health/Recommendations/Rec, 11.asp
28. Luban NLC: Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001; 38:34-45
29. AuBuchon JP: Pathogen inactivation in cellular blood components: Clinical trials and implications of introduction to transfusion medicine. Vox Sang 2002; 83:271-6